Press Releases

Apr 29,

ABBOTT'S BREAKTHROUGH DISSOLVING STENT RECEIVES FDA APPROVAL FOR ARTERIES BELOW THE KNEE

Apr 17, 2024 *****

ABBOTT REPORTS FIRST-QUARTER 2024 RESULTS AND RAISES MIDPOINT OF FULL-YEAR GUIDANCE RANGES

Apr 2, 2024

ABBOTT RECEIVES FDA APPROVAL FOR TRICLIP™, FIRST-OF-ITS-KIND DEVICE TO REPAIR LEAKY TRICUSPID HEART VALVE

Apr 1, 2024

ABBOTT RECEIVES FDA CLEARANCE FOR WHOLE BLOOD RAPID TEST TO HELP WITH ASSESSMENT OF CONCUSSION AT THE PATIENT'S BEDSIDE

Mar 27, 2024



ABBOTT HOSTS CONFERENCE CALL FOR FIRST-QUARTER EARNINGS

Mar 25, 2024

ABBOTT RECEIVES CE MARK FOR ITS GROUNDBREAKING ASSERT-IQ™ INSERTABLE CARDIAC MONITOR, EXPANDING AVAILABILITY OF LONG-TERM MONITORING FOR IRREGULAR HEART RHYTHMS

Mar 6, 2024

REAL-WORLD DATA SHOW ABBOTT'S FREESTYLE LIBRE® SYSTEMS AND GLP-1 MEDICINES WORK BETTER TOGETHER FOR PEOPLE WITH TYPE 2 DIABETES

Mar 4, 2024



ABBOTT EXTENDS INNOVATIVE HEALTH PARTNERSHIP WITH REAL MADRID AND THE REAL MADRID FOUNDATION

Feb 16, 2024
ABBOTT DECLARES 401ST CONSECUTIVE QUARTERLY DIVIDEND
Feb 13, 2024
FDA ADVISORY COMMITTEE VOTES IN FAVOR OF ABBOTT'S FIRST-OF-ITS-KIND TRICLIP™ SYSTEM TO TREAT PEOPLE WITH A LEAKY TRICUSPID HEART VALVE
Feb 1, 2024
NEW STUDY SHOWS MIXED REALITY TECHNOLOGY FOR BLOOD DONATION FROM ABBOTT AND BLOOD CENTERS OF AMERICA HELPS EASE STRESS, ENCOURAGES PEOPLE TO DONATE AGAIN
Jan 31, 2024
ABBOTT LAUNCHES NEW PROTALITY™ BRAND TO SUPPORT ADULTS ON THEIR WEIGHT LOSS JOURNEY
Jan 25, 2024
ABBOTT LAUNCHES WORLD'S SMALLEST RECHARGEABLE SYSTEM WITH REMOTE PROGRAMMING CAPABILITIES TO TREAT MOVEMENT DISORDERS¹+
Jan 24, 2024
ABBOTT REPORTS FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS; ISSUES 2024 FINANCIAL OUTLOOK
Jan 18,
ABBOTT'S PROCLAIM™ DRG NEUROSTIMULATION SYSTEM OFFERS EXPANDED MRI ACCESS FOR PEOPLE SUFFERING FROM CHRONIC PAIN
Jan 18, 2024
ABBOTT ANNOUNCES FIRST GLOBAL PROCEDURES IN A CLINICAL TRIAL OF ITS VOLT™ PULSED FIELD ABLATION SYSTEM TO TREAT PATIENTS WITH ABNORMAL HEART RHYTHMS

TANDEM DIABETES CARE'S T:SLIM X2™ INSULIN PUMP IS THE FIRST AUTOMATED INSULIN DELIVERY SYSTEM TO INTEGRATE WITH ABBOTT'S NEW FREESTYLE LIBRE® 2 PLUS SENSOR
Jan 3, 2024 ABBOTT HOSTS CONFERENCE CALL FOR FOURTH-QUARTER EARNINGS
Dec 18, 2023 ABBOTT TO PRESENT AT J.P. MORGAN HEALTHCARE CONFERENCE
Dec 15, 2023 ABBOTT INCREASES QUARTERLY DIVIDEND FOR 52ND CONSECUTIVE YEAR
Dec 14, 2023 ABBOTT'S NEW LAB AUTOMATION SYSTEM, GLP SYSTEMS TRACK, RECEIVES FDA APPROVAL, PROVIDING LABS AND PATIENTS WITH FASTER RESULTS
Nov 13, 2023 LATE-BREAKING DATA SHOW AN ASPIRIN-FREE MEDICATION REGIMEN BENEFITS PEOPLE WITH ABBOTT'S HEARTMATE 3™ HEART PUMP
Nov 8, 2023 PARTICIPANTS IN ABBOTT'S FOOD AS MEDICINE PROGRAM SHOWED CLINICALLY SIGNIFICANT IMPROVEMENTS IN MANAGING DIABETES
Nov 2, 2023 ABBOTT RECEIVES FDA APPROVAL FOR HPV TEST TO RUN ON ALINITY M, OFFERING PRIMARY HPV SCREENING AND ASSESSMENT OF HIGH-RISK CANCER-CAUSING TYPES OF HPV
Nov 1, 2023 ABBOTT AND SHERRI SHEPHERD: MILLIONS NOT USING AFFORDABLE DIABETES TECHNOLOGY « 1 2 3 4 5 6 »